Axitinib Drug Asset Due Diligence Report 2026

This Axitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

260

Registered trials

384

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Axitinib can convert its Small molecule drug profile and VEGFR1 x VEGFR2 x VEGFR3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Axitinib (query alias: axitinib)
Modality / target	Small molecule drug; VEGFR1 x VEGFR2 x VEGFR3; VEGFR1 antagonists, VEGFR2 antagonists, VEGFR3 antagonists
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	Akeso Biopharma Co., Ltd., Pfizer Italia Srl, Accord Healthcare SL

The MCP disease footprint includes Metastatic Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Renal Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07607561	Phase 2	Not yet recruiting	50	Change in Central Subfield Thickness
ChiCTR2600125307	Phase 2	Not yet recruiting	28	2-year Progression free survival
NCT07630363	Phase 1/2	Not yet recruiting	40	Objective Response Rate (ORR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Phase 1/2; n=5; evaluation: not stated. Reported fields: -; -; Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) = 1 Participants

Second-line TKI therapy following first-line immune checkpoint inhibitor combinations in metastatic RCC: A systematic review and meta-analysis of safety outcomes.

Not Applicable; n=1093; evaluation: Positive. Reported fields: Grade ≥3 adverse events = 30.0 % ; Grade ≥3 adverse events = 60.0 % ; Grade ≥3 adverse events = 48.0 %

Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.

Not Applicable; n=1007; evaluation: Positive. Reported fields: mOS = 58.4 month ; mOS = 56.7 month

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Axitinib addresses Metastatic Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Renal Cell Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-09-13	Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer	Approved	Financial terms not disclosed
2021-08-27	Akeso, Inc. Works with Pfizer to Conduct a Clinical Research of Cadonilimab (Bi-specific Antibody) with Combination of Axitinib for the First-line Treatment of Advanced / Metastatic Renal Clear Cell C	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Eye drop composition comprising novel molecular association of axitinib and method for preparing the same”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO